Plasma Cell-Free Nucleosome Profiling for SCLC Subtyping
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and monitoring small cell lung cancer (SCLC) and autoimmune hepatitis (AIH) rely heavily on invasive procedures like biopsies, which are not always feasible or timely, limiting the ability to identify subtype-specific therapies and treatment responses.
Innovation Solution
The use of cell-free DNA chromatin immunoprecipitation and sequencing (cfChIP-Seq) to analyze blood samples for epigenetic markers, such as histone modifications, to determine disease load and subtype, allowing non-invasive classification and monitoring of SCLC and AIH.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If invasive biopsy procedures are used to diagnose and monitor SCLC and AIH, then diagnostic accuracy and subtype identification are improved, but patient morbidity and procedural complexity increase
Solution Approach 1:
The patent uses cell-free DNA (cfDNA) as an intermediary substance that carries epigenetic information from tumor cells or damaged hepatocytes into the bloodstream. By analyzing cfDNA extracted from blood samples, the invention enables non-invasive detection of disease presence, subtype classification, and treatment monitoring without requiring direct tissue sampling, thus resolving the contradiction between diagnostic accuracy and patient morbidity
Solution Approach 2:
The patent creates a molecular copy of the disease state through cfDNA analysis. Instead of directly examining tissue samples via biopsy, the invention analyzes copies of genetic material (cfDNA) that circulate in the blood and reflect the epigenetic state of the original tissue. This copying approach maintains diagnostic information while eliminating the need for invasive procedures
2Measurement precision
If invasive biopsy procedures are performed to determine treatment response, then accurate monitoring is achieved, but treatment time delays and procedural risks increase
Solution Approach 1:
The patent enables continuous monitoring of treatment response by repeatedly analyzing cfDNA from blood samples at different time points. This continuous action allows clinicians to track changes in disease burden and treatment efficacy over time without interrupting treatment with invasive biopsy procedures, thus eliminating treatment delays while maintaining monitoring accuracy
Solution Approach 2:
By using cfDNA as a mediator that can be easily accessed from blood samples, the invention enables frequent and rapid assessment of treatment response. The cfDNA provides real-time information about tumor burden or liver damage without requiring time-consuming biopsy procedures, thus resolving the contradiction between monitoring accuracy and treatment time delays
3Reliability
If cfDNA mutational analysis is performed, then cancer detection is improved, but subtype classification capability is insufficient
Solution Approach 1:
The patent shifts the analytical parameter from DNA sequence mutations to DNA epigenetic modifications (histone modifications, nucleosome positioning). This parameter change enables the preservation of cancer detection reliability while simultaneously capturing transcriptomic subtype information, as epigenetic marks reflect the transcriptional state of the cells of origin without requiring direct tissue analysis
4Measurement precision
If liver biopsy is performed to confirm AIH diagnosis and monitor remission, then diagnostic and monitoring accuracy are improved, but patient morbidity and procedural complexity increase
Solution Approach 1:
The patent uses cfDNA from blood samples as an intermediary to detect AIH and monitor treatment response. By analyzing epigenetic modifications in cfDNA, the invention provides accurate diagnosis and monitoring without requiring complex liver biopsy procedures, thus resolving the contradiction between diagnostic accuracy and procedural complexity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides accurate, non-invasive methods for determining disease load and subtype, correlating with tumor burden and treatment response, enabling personalized therapy and monitoring.
Implementation Method 1
chromatin immunoprecipitation and sequencing of cell-free nucleosomes from human plasma (cfChIP-seq)
Implementation Method 2
tri-methylation of histone 3 lysine 4 (H3K4me3) is a well characterized histone modification, marking transcription start sites (TSS) of genes that are poised or actively transcribed
Data Source
AI summary
Methods of determining disease load or type in a subject suffering from a disease associated with cell death of a specific tissue or cell type are provided. Methods of determining a cell free DNA chromatin immunoprecipitation and sequencing (cfChIP-Seq) marker and methods of classifying a subject suffering from a disease are also provided.